S&P 500   3,801.54
DOW   30,952.03
QQQ   316.63
S&P 500   3,801.54
DOW   30,952.03
QQQ   316.63
S&P 500   3,801.54
DOW   30,952.03
QQQ   316.63
S&P 500   3,801.54
DOW   30,952.03
QQQ   316.63
Log in

Harrow Health Stock Forecast, Price & News

-0.22 (-2.77 %)
(As of 01/19/2021 03:23 PM ET)
Today's Range
Now: $7.73
50-Day Range
MA: $6.26
52-Week Range
Now: $7.73
Volume7,299 shs
Average Volume340,050 shs
Market Capitalization$199.02 million
P/E RatioN/A
Dividend YieldN/A
Harrow Health, Inc., together with its subsidiaries, develops, produces, and sells medications for unmet needs primarily in the United States. The company primarily provides ophthalmology based formulations to physicians and patients; and sterile and non-sterile compounded medications. It also develops and commercializes therapeutics for treating ocular surface diseases; and non-intravenous sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. Its products portfolio includes topical eye drop drug candidates, including SURF-100 and SURF-200; SURF-300, an oral capsule for treating patients suffering from ocular surface diseases, and DED signs and symptoms; Klarity drops to protect and rehabilitate the ocular surface pathology for patients with DED; MELT-100, a drug that is administered sublingually for conscious sedation during cataract surgery; MAY-66 that is used for the treatment of symptoms associated with Peyronie's disease; MAY-44, a non-estrogen topical analgesic gel; and other drug candidates for rare diseases. In addition, the company engages in the development of MAY-88, an oral anhydrous extend release suspension of pentosan polysulfate sodium for interstitial cystitis. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was founded in 1998 and is headquartered in San Diego, California.


Overall MarketRank

1.75 out of 5 stars

Analyst Opinion: 3.5Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:HROW



Sales & Book Value

Annual Sales$51.17 million
Book Value$1.09 per share


Net Income$170,000.00


Market Cap$199.02 million
Next Earnings Date3/12/2021 (Estimated)
-0.22 (-2.77 %)
(As of 01/19/2021 03:23 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HROW News and Ratings via Email

Sign-up to receive the latest news and ratings for HROW and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Harrow Health (NASDAQ:HROW) Frequently Asked Questions

How has Harrow Health's stock price been impacted by COVID-19?

Harrow Health's stock was trading at $4.76 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, HROW stock has increased by 62.4% and is now trading at $7.73.
View which stocks have been most impacted by COVID-19

Is Harrow Health a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harrow Health in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Harrow Health stock.
View analyst ratings for Harrow Health
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Harrow Health?

Wall Street analysts have given Harrow Health a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Harrow Health wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Harrow Health's next earnings date?

Harrow Health is scheduled to release its next quarterly earnings announcement on Friday, March 12th 2021.
View our earnings forecast for Harrow Health

How were Harrow Health's earnings last quarter?

Harrow Health, Inc. (NASDAQ:HROW) released its quarterly earnings results on Monday, November, 9th. The company reported $0.32 EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.11) by $0.43. The firm had revenue of $14.40 million for the quarter, compared to analyst estimates of $8.68 million. Harrow Health had a negative net margin of 3.94% and a negative return on equity of 3.52%.
View Harrow Health's earnings history

What price target have analysts set for HROW?

1 equities research analysts have issued 12 month price objectives for Harrow Health's shares. Their forecasts range from $14.00 to $14.00. On average, they expect Harrow Health's stock price to reach $14.00 in the next year. This suggests a possible upside of 81.1% from the stock's current price.
View analysts' price targets for Harrow Health
or view Wall Street analyst' top-rated stocks.

Who are some of Harrow Health's key competitors?

What other stocks do shareholders of Harrow Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harrow Health investors own include NVIDIA (NVDA), Aldeyra Therapeutics (ALDX), OPKO Health (OPK), QUALCOMM (QCOM), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY), VBI Vaccines (VBIV), Exelixis (EXEL) and Mustang Bio (MBIO).

Who are Harrow Health's key executives?

Harrow Health's management team includes the following people:
  • Mr. Mark L. Baum, CEO & Director (Age 47, Pay $802.78k)
  • Mr. Andrew R. Boll C.F.A., C.M.A., CFA, CMA, CFO & Corp. Sec. (Age 38, Pay $539.78k)
  • Mr. John P. Saharek, Pres of ImprimisRx (Age 60, Pay $463.33k)
  • Mr. David Moufarrège, VP of Technology
  • Dr. Dennis E Saadeh Pharm.D., Chief of Formulation Strategy
  • Dr. Larry M. Dillaha, Chief Medical Officer
  • Mr. Andrew Livingston, Chief Innovation Officer

What is Harrow Health's stock symbol?

Harrow Health trades on the NASDAQ under the ticker symbol "HROW."

Who are Harrow Health's major shareholders?

Harrow Health's stock is owned by many different institutional and retail investors. Top institutional shareholders include Westside Investment Management Inc. (0.28%) and Baystate Wealth Management LLC (0.02%). Company insiders that own Harrow Health stock include Opaleye Management Inc and Robert J Kammer.
View institutional ownership trends for Harrow Health

Which major investors are selling Harrow Health stock?

HROW stock was sold by a variety of institutional investors in the last quarter, including Baystate Wealth Management LLC.
View insider buying and selling activity for Harrow Health
or view top insider-selling stocks.

Which major investors are buying Harrow Health stock?

HROW stock was purchased by a variety of institutional investors in the last quarter, including Westside Investment Management Inc..
View insider buying and selling activity for Harrow Health
or or view top insider-buying stocks.

How do I buy shares of Harrow Health?

Shares of HROW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Harrow Health's stock price today?

One share of HROW stock can currently be purchased for approximately $7.73.

How big of a company is Harrow Health?

Harrow Health has a market capitalization of $199.02 million and generates $51.17 million in revenue each year. The company earns $170,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis. Harrow Health employs 133 workers across the globe.

What is Harrow Health's official website?

The official website for Harrow Health is www.harrowinc.com.

How can I contact Harrow Health?

Harrow Health's mailing address is 102 Woodmont Blvd. Suite 610, Nashville TN, 37205. The company can be reached via phone at 615-733-4730 or via email at [email protected]

This page was last updated on 1/19/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.